ACLX - Arcellx, Inc.
IEX Last Trade
77.935
0.385 0.494%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:27 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$77.55
0.39
0.50%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
2.70%
1 Month
-13.23%
3 Months
-8.30%
6 Months
44.23%
1 Year
44.07%
2 Year
161.92%
Key data
Stock price
$77.94
DAY RANGE
N/A - N/A
52 WEEK RANGE
$50.66 - $107.37
52 WEEK CHANGE
$34.71
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Rami Elghandour
Region: US
Website: arcellx.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: arcellx.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.
Recent news